STEVENSON, Md., May 17, 2013 (GLOBE NEWSWIRE) -- Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of Amyris, Inc. ("Amyris" or the "Company") (Nasdaq:AMRS) common stock during the period between April 29, 2011 and February 8, 2012, inclusive (the "Class Period").
If you have suffered a net loss from investment in Amyris, Inc. common stock purchased on or after April 29, 2011, and held through any of the revelations of negative information on November 1, 2011 and/or February 9, 2012, as described below, you may obtain additional information about this lawsuit and your ability to become a lead plaintiff by contacting Brower Piven at www.browerpiven.com, by email at firstname.lastname@example.org, by calling 410/415-6616, or at Brower Piven, A Professional Corporation, 1925 Old Valley Road, Stevenson, Maryland 21153. Attorneys at Brower Piven have combined experience litigating securities and class action cases of over 60 years.
No class has yet been certified in the above action. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff no later than July 15, 2013 and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement and how much of a settlement to accept for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the Company during the Class Period.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants falsely representing during the Class Period that the Company had the ability to produce Biofene in commercially meaningful volumes. According to the complaint, following the Company's November 1, 2011 disclosure that it would not be able to produce Biofene in the quantities previously represented but that it had identified and learned to address issues that would allow it to raise the volumes, and the Company's February 9, 2012 disclosure of a further slowdown in Biofene production and the need to raise funds, the value of Amyris shares declined significantly.
If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven Brower Piven, A Professional Corporation Stevenson, Maryland 410/415-6616 email@example.comSource: Brower Piven, A Professional Corporation